Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Inhibikase Therapeutics (NASDAQ:IKT – Free Report) from a strong sell rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

A number of other equities research analysts have also issued reports on the stock. Chardan Capital restated a “neutral” rating and set a $1.50 price target on shares of Inhibikase Therapeutics in a report on Thursday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Inhibikase Therapeutics in a research note on Thursday, November 12th. Three equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.75.

View Our Latest Stock Report on Inhibikase Therapeutics

Inhibikase Therapeutics Trading Down 4.6%

Shares of IKT opened at $1.45 on Friday. The business’s 50-day moving average price is $1.87 and its 200 day moving average price is $1.93. The stock has a market capitalization of $203.39 million, a P/E ratio of -3.62 and a beta of 0.94. Inhibikase Therapeutics has a 1-year low of $1.40 and a 1-year high of $2.61.

Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. On average, research analysts predict that Inhibikase Therapeutics will post -0.41 earnings per share for the current year.

Hedge Funds Weigh In On Inhibikase Therapeutics

A number of large investors have recently made changes to their positions in IKT. Kalehua Capital Management LLC raised its stake in shares of Inhibikase Therapeutics by 118.4% during the 1st quarter. Kalehua Capital Management LLC now owns 3,821,890 shares of the company’s stock worth $6,421,000 after purchasing an additional 2,071,890 shares in the last quarter. SummitTX Capital L.P. acquired a new stake in shares of Inhibikase Therapeutics during the 1st quarter valued at about $2,561,000. Ally Bridge Group NY LLC acquired a new stake in shares of Inhibikase Therapeutics during the 1st quarter valued at about $2,226,000. Soleus Capital Management L.P. grew its stake in shares of Inhibikase Therapeutics by 3.2% in the 3rd quarter. Soleus Capital Management L.P. now owns 11,225,000 shares of the company’s stock valued at $23,067,000 after buying an additional 350,000 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Inhibikase Therapeutics in the 2nd quarter valued at approximately $615,000. Institutional investors and hedge funds own 3.81% of the company’s stock.

About Inhibikase Therapeutics

(Get Free Report)

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.

Further Reading

Analyst Recommendations for Inhibikase Therapeutics (NASDAQ:IKT)

Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.